Breaking News
September 23, 2018 - Can machine learning bring more humanity to health care?
September 23, 2018 - Body organs undergo structural changes in response to diet
September 23, 2018 - Genetic polymorphisms linked with muscle injury and stiffness
September 23, 2018 - As states try to rein in drug spending, feds slap down one bold Medicaid move
September 22, 2018 - Why Eczema Is Tougher to Treat for Black Patients
September 22, 2018 - Team reveals that human genome could contain up to 20 percent fewer genes
September 22, 2018 - USC research uncovers previously unknown genetic risk factor for Alzheimer’s disease
September 22, 2018 - Novel method achieves accurate and precise temperature estimation in fat-containing tissues
September 22, 2018 - BSI accredits Oxehealth’s vital signs measurement software as Class IIa medical device
September 22, 2018 - Evolution of psychiatric disorders and human personality traits
September 22, 2018 - Obesity in early puberty doubles asthma risk for boy’s future offspring
September 22, 2018 - World’s most advanced real-time patient monitoring platform receives key US patent
September 22, 2018 - Study explores connection between sexuality and cognitive status in older adults
September 22, 2018 - LSTM partners with TB Alliance to develop novel TB drug regimens
September 22, 2018 - Annual wellness visits improve delivery of preventive services in elderly population
September 22, 2018 - CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma
September 22, 2018 - Hispanic communities with high proportions of Hispanics face more cardiovascular-related death
September 22, 2018 - Vici syndrome – Genetics Home Reference
September 22, 2018 - Single-dose drug can shorten flu symptoms by about a day, studies suggest
September 22, 2018 - AMSBIO launches circulating tumor DNA Reference Standards
September 22, 2018 - Sandalwood mimicking odorant could stimulate hair growth in humans
September 22, 2018 - Overlooked immune cells could play a key role in cancer immunotherapy, claims new study
September 22, 2018 - Study reveals prevalence of diagnosed type 1 and type 2 diabetes among American adults
September 22, 2018 - Researchers develop fast detection strategy to know type of virus acquired by patients
September 22, 2018 - Global Prevalence of Insufficient Activity 27.5 Percent
September 22, 2018 - Strategies to protect bone health in hematologic stem cell transplant recipients
September 22, 2018 - Brigham Genomic Medicine program unravels 30 medical mysteries
September 22, 2018 - New system harnesses power of bubbles to destroy dangerous biofilms
September 22, 2018 - Inflammation plays crucial role in preventing heart attacks and strokes, study reveals
September 22, 2018 - Calorie dense, nutrient deficient meals common across the world
September 22, 2018 - Researchers develop technology to study behavior of implants without animal testing
September 22, 2018 - First gut bacteria in newborns may have lasting effect on ability to ward off chronic diseases
September 22, 2018 - Detection of BFD virus in parrots in 8 new countries raises concerns for threatened species
September 22, 2018 - Insulin treatment shows great potential against chronic bowel inflammation
September 22, 2018 - ‘Liking Gap’ Might Stand in Way of New Friendships
September 22, 2018 - Simple factors that can avoid harmful side effects in type 2 diabetes
September 22, 2018 - ALSAM Foundation invests additional $2 million for drug discovery and development projects
September 22, 2018 - Study findings may advance discussion of how to effectively curb human-wildlife conflict
September 22, 2018 - Dopamine neurons may involve in conditions ranging from Parkinson’s disease to schizophrenia
September 22, 2018 - Protein C and Protein S Tests: MedlinePlus Lab Test Information
September 22, 2018 - Obesity and diabetes—two reasons why we should be worried about the plastics that surround us
September 22, 2018 - Concern over fussy eating prompts parents to use non-responsive feeding practices
September 22, 2018 - Novel mathematical approach uncovers existence of unsuspected biological cycles
September 22, 2018 - Cancer Research UK invests £14 million to transform London into cancer biotherapeutics hub
September 22, 2018 - Scientists predict how well the body will fight lung cancer by analyzing immune cell shapes
September 22, 2018 - New outbreak of rare eye disease identified in contact lens wearers
September 22, 2018 - Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 22, 2018 - Research finds divide in dental health accessibility between city and regional areas
September 22, 2018 - Premature babies show better brain development when fed breast milk, finds study
September 22, 2018 - Novel system uses AI to detect abnormalities in fetal hearts
September 22, 2018 - UNC scientists reveal new approach to prevent obesity and diabetes
September 22, 2018 - CWRU receives NIH grant to learn how non-coding genes contribute to spread of colorectal cancer
September 22, 2018 - Scientists better understand influenza virus and how it spreads
September 22, 2018 - Scientists to focus on length of time when a person is alive and healthy
September 22, 2018 - Study shows positive financial impacts of Medicaid expansion for low-income Michigan residents
September 22, 2018 - Innovative approach for developing vaccine against most prevalent human malaria parasite
September 22, 2018 - Research scientist at Kessler Foundation receives $10,000 grant to study aphasia after stroke
September 22, 2018 - New findings on characteristics of Burning Mouth Syndrome
September 22, 2018 - Study sheds light on molecular mechanisms underlying progression of prion diseases
September 22, 2018 - Innovation Fund Denmark supports research project that aims to fight Clostridium difficile diarrhea
September 22, 2018 - Survey estimates caregiving costs for family members
September 22, 2018 - Inhibiting NF-kB improves heart function in a mouse model of Duchenne muscular dystrophy
September 22, 2018 - Introducing new EMR system may affect several aspects of clinic workflow
September 22, 2018 - Study finds why some human genes are more popular with biomedical researchers
September 22, 2018 - Finding epigenetic signature appears to predict inflammation risk in serious type of IBD
September 22, 2018 - Researchers develop light-based technique to measure very weak magnetic fields
September 22, 2018 - UAB researchers study dysfunction of the immune system associated with NSAID carprofen
September 22, 2018 - QIAGEN and DiaSorin launch automated, CE-marked workflow for high-throughput TB screening
September 22, 2018 - EFS checklist provides user-friendly tool for evaluating feeding skills in preterm infants
September 22, 2018 - Family history in blacks, Latinos associated with higher risk of AFib
September 22, 2018 - Researchers identify new genetic disorder in a human patient
September 22, 2018 - Cardiac MR With Contrast Feasible in Developing World
September 22, 2018 - Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy people
September 21, 2018 - Children with asthma found to be disadvantaged in education and future occupation
September 21, 2018 - Interaction of chemical slurry and ancient shale in fracking wastewater causes radioactivity
September 21, 2018 - Scientists use mice to study transmission of Lyme disease bacteria by infected ticks
September 21, 2018 - Researchers find that sample size is key factor determining accuracy of study results
September 21, 2018 - Study shows how the drive to eat overpowers the brain’s signal to stop
September 21, 2018 - 30 Million Americans Now Have Diabetes
September 21, 2018 - Thousands of breast cancer gene variants engineered and analyzed
Enzalutamide Safe In Seizure-Prone Prostate CA Patients

Enzalutamide Safe In Seizure-Prone Prostate CA Patients

image_pdfDownload PDFimage_print

Action Points

  • The androgen receptor inhibitor enzalutamide (Xtandi) did not raise seizure incidence when used at a dose of 160 mg/day in men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, in a multicenter, multinational trial.
  • Note that the data, along with the previously established efficacy profile, suggest that enzalutamide does not predispose to seizures and may be safely used in men with metastatic prostate cancer who have risk factors for seizure.

In men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, the androgen receptor inhibitor enzalutamide (Xtandi) didn’t raise seizure incidence when used at a dose of 160 mg/day, researchers found in a manufacturer-sponsored study.

Confirmed seizure incidence in the Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide (UPWARD) was 2.6 per 100 patient-years, according to Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

That’s about the same as the incidence previously calculated in a large retrospective analysis in the U.S., at 2.8 per 100 patient-years in patients with mCRPC and seizure risk factors who never took the drug, Slovin and colleagues reported online in JAMA Oncology.

“These data suggest that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors and is an option for patients with seizure risk factors,” the researchers wrote. “However, it should be used with caution and input from neurology specialists.”

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they added.

Jim Hu, MD, MPH, of New York Presbyterian/Weill Cornell Medicine in New York City, who wasn’t involved in the study, noted that the results contrast to those of a prior study, but they do suggest that “enzalutamide does not predispose to seizure. This demonstrates that enzalutamide may be safely used in men with metastatic prostate cancer who have risk factors for seizure.”

UPWARD was initiated following requests for additional safety information from the FDA and the European Medicines Agency. Although enzalutamide is known to prolong survival in men with mCRPC, phase I and II studies reported seizures in 3 of 140 (2%) enzalutamide-treated patients at doses greater than 360 mg/day.

Controlled clinical trials such as AFFIRM, PREVAIL, TERRAIN, and STRIVE have shown that with 160 mg of oral enzalutamide daily, only 0.5% of patients experienced seizure. However, patients with a history of seizure or risk factors were excluded from these trials, the researchers noted.

For UPWARD, they evaluated 423 patients at 73 sites in 20 countries, all of whom had at least one risk factor for seizure, including medications that lowered seizure threshold (57.2%); history of brain injury (26.5%); and history of cerebrovascular accident or transient ischemic attack (22.2%).

All patients received oral enzalutamide at a dose of 160 mg/day for an initial 4-month treatment period, and were given the option to extend treatment for one year.

Overall, 4 out of 366 evaluable patients (1.1%) had at least one confirmed seizure within 4 months of starting enzalutamide. The seizures were considered enzalutamide-related in 3 of the 4 patients. In addition, 3 patients (0.8%) had a seizure in the 4-month period after the study ended.

All 423 patients were included in the safety analysis. The majority (84.4%) experienced at least one treatment-emergent adverse event: 33.3% had at least one serious treatment-emergent adverse event, and 6.9% had at least one drug-related serious adverse event.

A total of 66 patients (15.6%) permanently discontinued treatment as a result of a drug-related AE, and three of these patients had a seizure, the researchers reported.

During the 4-month study period or within 30 days of the treatment ending, there were 38 deaths (9%), four of which were considered possibly drug-related. One patient died of cerebral hemorrhage, one of mCRPC progression, one experienced sudden cardiac death, and another had general deterioration. No seizure-related deaths were reported.

Study limitations included the fact that a randomized controlled trial wasn’t feasible, and that predisposing risk factors for seizure such as a history of seizure or of brain arteriovenous malformations were underrepresented, the researchers said.

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they concluded.

This study was funded by Astellas Pharma and Medivation (acquired by Pfizer in September 2016), the co-developers of enzalutamide. Both sponsors participated in the design and conduct of the study as well as analysis and interpretation of the data, approval of the manuscript, and decision to submit for publication. Lead author Slovin reported a relationship with Bayer AG. A number of co-authors also reported relationships with industry, including Astellas Pharma, Medivation, and Pfizer.

2017-12-11T15:30:00-0500

Tagged with:

About author

Related Articles